Status: Recruiting
Rarecells Molecular Biomarkers for Early Detection of Lung Cancer
Early diagnosis of lung cancer is a public health priority. Additionally, early detection of recurrences after treatment is crucial for optimizing disease management. This study seeks to demonstrate the accuracy of the Rarecells ISET® circulating tumor cells DNA (CTC-DNA), combined with circulating tumor DNA (ctDNA), for the early diagnosis of lung cancer.
Participants needed: 50
Trial details
Age: 35-85Biological sex: AllType: ObservationalSponsor: Rarecells Diagnostics SASUpdated: Jun 11, 2025Locations: 1
Eligibility criteria
Male or female aged between 35 and 85 years [+6]
Patient diagnosed and/or treated previously for lung cancer or another cancer, r... [+3]